CAMP4 Therapeutics Corporation Common StockCAMP
CAMP
About: Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
63.76% more ownership
Funds ownership: 0% [Q3] → 63.76% (+63.76%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CAMP.
Financial journalist opinion
Based on 3 articles about CAMP published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D.
Neutral
GlobeNewsWire
1 week ago
CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
Neutral
GlobeNewsWire
1 week ago
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
Neutral
GlobeNewsWire
1 month ago
CAMP4 to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
2 months ago
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today provided corporate updates and key objectives for 2025.
Neutral
GlobeNewsWire
3 months ago
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced that management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference to be held at the Lotte New York Palace Hotel in New York City December 3rd – 5th, 2024.
Neutral
GlobeNewsWire
4 months ago
CAMP4 Reports Third Quarter 2024 Financial Results
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M
Positive
Benzinga
4 months ago
CAMP4 Analyst Highlights Rare Disease Platform Potential
In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.
Neutral
GlobeNewsWire
5 months ago
CAMP4 Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4's common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Positive
Seeking Alpha
5 months ago
Camp4 Therapeutics Targets IPO On Early Positive Results
Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive Phase 1 safety results for treating urea cycle disorders, with no concerning safety trends observed. The urea cycle disorders market is moderate in size, with a low expected growth rate, but Camp4 aims to broaden into larger markets.
Charts implemented using Lightweight Charts™